Can Fite Biopharma Ltd (NYSEAMERICAN:CANF) was the target of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 153,200 shares, a decline of 63.1% from the February 28th total of 414,767 shares. Based on an average trading volume of 164,129 shares, the days-to-cover ratio is presently 0.9 days.
Shares of CANF stock opened at $1.45 on Tuesday. The firm has a market capitalization of $32.28, a PE ratio of 6.24 and a beta of 1.94. Can Fite Biopharma has a fifty-two week low of $1.24 and a fifty-two week high of $2.75.
A hedge fund recently bought a new stake in Can Fite Biopharma stock. Meitav Dash Investments Ltd. acquired a new stake in Can Fite Biopharma Ltd (NYSEAMERICAN:CANF) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 155,000 shares of the biotechnology company’s stock, valued at approximately $240,000. Meitav Dash Investments Ltd. owned about 0.93% of Can Fite Biopharma as of its most recent SEC filing. 5.12% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This report was first posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.tickerreport.com/banking-finance/3303398/can-fite-biopharma-ltd-canf-short-interest-down-63-1-in-march.html.
About Can Fite Biopharma
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
Receive News & Ratings for Can Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.